Prenetics Global Limited(PRE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.17 | Insider Own | 22.49% | Shs Outstand | 15.2M | Perf Week | -9.17% |
| Market Cap | 0.41B | Forward P/E | - | EPS next Y | 52.43% | Insider Trans | 1.25% | Shs Float | 13.3M | Perf Month | 24.46% |
| Enterprise Value | 0.30B | PEG | - | EPS next Q | -0.8 | Inst Own | 7.06% | Short Float | 4.44% | Perf Quarter | 22.91% |
| Income | -0.07B | P/S | 2.85 | EPS this Y | 8.71% | Inst Trans | -17.14% | Short Ratio | 2.59 | Perf Half Y | 15.08% |
| Sales | 0.14B | P/B | 4.26 | EPS next 5Y | - | ROA | -39.86% | Short Interest | 0.59M | Perf YTD | 50.22% |
| Book/sh | 5.56 | P/C | 3.71 | EPS past 3/5Y | 58.51% 34.71% | ROE | -57.62% | 52W High | -13.14% ($27.24) | Perf Year | 134.72% |
| Cash/sh | 6.38 | P/FCF | - | Sales past 3/5Y | 91.46% -23.93% | ROIC | -72.58% | 52W Low | 188.54% ($8.20) | Perf 3Y | 196.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.43% | Gross Margin | 63.22% | Volatility(W/M) | 5.59% 7.78% | Perf 5Y | -79.07% |
| Dividend TTM | - | EV/Sales | 2.08 | Sales Y/Y TTM | 182.05% | Oper. Margin | -35.48% | ATR (14) | 1.6 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.66 | EPS Q/Q | 49.36% | Profit Margin | -47.43% | RSI (14) | 54.83 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.04 | Sales Q/Q | 210.67% | SMA20 | 2.7% ($23.04) | Beta | 0.34 | Target Price | $35.6 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/18 | SMA50 | 15.64% ($20.46) | Rel Volume | 0.83 | Prev Close | $24.27 |
| Employees | 98 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 36.9% -6.74% | SMA200 | 27.26% ($18.59) | Avg Volume(3M) | 0.23M | Price | $23.66 |
| IPO | 2021/7/16 | Option/Short | Yes/Yes | Trades | 2111 | Volume | 188,210 | Change | -2.51% |
Company
PRE is a Consumer Defensive sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A global health sciences company focused on consumer health and wellness along with genetic testing. It operates the health and wellness brand iMe8, the sports nutrition distribution brand Europa, and the next-generation sequencing–based consumer genetic testing brand CircleDNA, with a focus on the direct-to-consumer health market.
Over the past 1 year, on the higher side
13% below its 1-year high.
PRE has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +196.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 7.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BCOR 0.00%
IWC 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
IAU 65.4B
PFF 12.8B
SGOL 7.5B
BLCR 6.8B
FPE 6.3BIt ranks #4 in the industry
Based on market cap of $406M.
PRE $406M PER -
KHC $29B PER -
GIS $19B PER -
MKC $14B PER 8.5
FAQ
What kind of company is PRE?
PRE belongs to the Consumer Defensive sector and operates in the Packaged Foods industry.
What is the market cap of PRE?
The market cap of PRE is approximately $406M, ranking 3,391 within its sector.
What is the 52-week high and low for PRE?
PRE has recorded a 52-week high of $27.24 and a low of $8.20.
